INOFEA

INOFEA is the technology addresses a wide range of biotech applications for the health industry.

INOFEA AG is a Swiss biotech company founded in 2014 in Basel by a group of entrepreneurs and scientists as a spin-off from the School of Life Sciences, University of Applied Sciences and Arts, Northwestern Switzerland (FHNW), led by CEO Dr Yves Dudal. At INOFEA, they empower enzymes. Together with their team of scientists led by Dr Patrick Shahgaldian, Professor at FHNW and CSO of INOFEA, and with the help of their investors, they have developed enzzen, a patented platform technology capable to fit enzymes to in vivo and process conditions. They’ve created INOFEA from the desire to meet a critical need related to enzyme lack of stability and robustness: the possibility to provide enzymes with resistance to in vivo and process conditions, so that they could be fully deployed in the health industry.